MSMichael D. Sharpe

Michael D. Sharpe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael D. Sharpe has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effect of Sepsis on the Erythrocyte

    by Ryon M. Bateman, Michael D. Sharpe, Mervyn Singer, Christopher G. Ellis

    Sepsis induces a wide range of effects on the red blood cell (RBC). Some of the effects including altered metabolism and decreased 2,3-bisphosphoglycerate are preventable with appropriate treatment, whereas others, including decreased erythrocyte deformability and redistribution of membrane phospholipids, appear to be permanent, and factors in RBC clearance. Here, we review the effects of sepsis on the erythrocyte, including changes in RBC volume, metabolism and hemoglobin’s affinity for oxygen, morphology, RBC deformability (an early indicator of sepsis), antioxidant status, intracellular Ca2+ homeostasis, membrane proteins, membrane phospholipid redistribution, clearance and RBC O2-dependent adenosine triphosphate efflux (an RBC hypoxia signaling mechanism involved in microvascular autoregulation). We also consider the causes of these effects by host mediated oxidant stress and bacterial virulence factors. Additionally, we consider the altered erythrocyte microenvironment due to sepsis induced microvascular dysregulation and speculate on the possible effects of RBC autoxidation. In future, a better understanding of the mechanisms involved in sepsis induced erythrocyte pathophysiology and clearance may guide improved sepsis treatments. Evidence that small molecule antioxidants protect the erythrocyte from loss of deformability, and more importantly improve septic patient outcome suggest further research in this area is warranted. While not generally considered a critical factor in sepsis, erythrocytes (and especially a smaller subpopulation) appear to be highly susceptible to sepsis induced injury, provide an early warning signal of sepsis and are a factor in the microvascular dysfunction that has been associated with organ dysfunction.


  • Open Access

    Sepsis impairs microvascular autoregulation and delays capillary response within hypoxic capillaries

    by Ryon M. Bateman, Michael D. Sharpe, Justin E. Jagger, Christopher G. Ellis

    Introduction: The microcirculation supplies oxygen (O2) and nutrients to all cells with the red blood cell (RBC) acting as both a deliverer and sensor of O2. In sepsis, a proinflammatory disease with microvascular complications, small blood vessel alterations are associated with multi-organ dysfunction and poor septic patient outcome. We hypothesized that microvascular autoregulation—existing at three levels: over the entire capillary network, within a capillary and within the erythrocyte—was impaired during onset of sepsis. This study had three objectives: 1) measure capillary response time within hypoxic capillaries, 2) test the null hypothesis that RBC O2-dependent adenosine triphosphate (ATP) efflux was not altered by sepsis and 3) develop a framework of a pathophysiological model. Methods: This was an animal study, comparing sepsis with control, set in a university laboratory. Acute hypotensive sepsis was studied using cecal ligation and perforation (CLP) with a 6-hour end-point. Rat hindlimb skeletal muscle microcirculation was imaged, and capillary RBC supply rate (SR = RBC/s), RBC hemoglobin O2 saturation (SO2) and O2 supply rate (qO2 = pLO2/s) were quantified. Arterial NOx (nitrite + nitrate) and RBC O2-dependent ATP efflux were measured using a nitric oxide (NO) analyzer and gas exchanger, respectively. Results: Sepsis increased capillary stopped-flow (p = 0.001) and increased plasma lactate (p < 0.001). Increased plasma NOx (p < 0.001) was related to increased capillary RBC supply rate (p = 0.027). Analysis of 30-second SR–SO2–qO2 profiles revealed a shift towards decreased (p < 0.05) O2 supply rates in some capillaries. Moreover, we detected a three- to fourfold increase (p < 0.05) in capillary response time within hypoxic capillaries (capillary flow states where RBC SO2 < 20 %). Additionally, sepsis decreased the erythrocyte’s ability to respond to hypoxic environments, as normalized RBC O2-dependent ATP efflux decreased by 62.5 % (p < 0.001). Conclusions: Sepsis impaired microvascular autoregulation at both the individual capillary and erythrocyte level, seemingly uncoupling the RBC acting as an “O2 sensor” from microvascular autoregulation. Impaired microvascular autoregulation was manifested by increased capillary stopped-flow, increased capillary response time within hypoxic capillaries, decreased capillary O2 supply rate and decreased RBC O2-dependent ATP efflux. This loss of local microvascular control was partially off-set by increased capillary RBC supply rate, which correlated with increased plasma NOx.


  • Open Access

    Oral and intravenous thyroxine (T4) achieve comparable serum levels for hormonal resuscitation protocol in organ donors: a randomized double-blinded study

    by Michael D. Sharpe, Barbara van Rassel, Wael Haddara

    Thyroxine (T4) administration is advocated in the management of organ donors; however, the bioavailability of oral thyroxine is unknown in this patient population. The primary objective of this study was to compare the percentage of the study time (from study drug administration to organ procurement) that patients in the oral vs the intravenous group required inotropic support. Secondary objectives included plasma levels of T3 and T4 and number of organs donated following oral vs intravenous T4 administration. Randomized double-blinded study. Adult medical-surgical intensive care unit. Thirty-two adult solid organ donors. Patients were randomized to receive either an oral or intravenous dose of T4 (2 μg·kg−1). All patients received an oral and intravenous study drug preparation, one of which was a placebo. The study was double-blinded, and randomization occurred in blocks of four and six. The number and duration of inotropic/vasopressor therapies and free serum levels of T3 and T4 were determined hourly until procurement. Following T4 administration, all patients remained on inotropic/vasopressor therapy for the same mean (SD) duration [93 (3)%] of the study period. There was a similar and gradual decrease in the number and dosages of inotropes/vasopressors required in both groups. There was no difference in T3 or T4 levels between groups. Oral bioavailability of T4 was 93% of the intravenous group at six hours and 91% overall. At six hours, the mean area under the curve for T4 was similar between the intravenous group [92.2 (33); 95% confidence interval (CI) 76 to 108.4] and the oral group [86.1 (14); 95% CI 79.4 to 92.8]. Orally administered T4 is well absorbed and achieves a bioavailability of approximately 91-93% of intravenous T4 in organ donors. Inotropic/vasopressor requirements and hemodynamic responses following oral or intravenous thyroxine administration were comparable. Oral T4 is suitable for hormonal therapy for organ donors. This trial was registered at www.clinicaltrials.gov: NCT00238030. L’administration de thyroxine (T4) est recommandée pour la prise en charge de donneurs d’organes; toutefois, nous ne connaissons pas la biodisponibilité de la thyroxine orale chez cette population de patients. L’objectif principal de cette étude était de comparer le pourcentage du temps (de l’administration du médicament à l’étude à l’approvisionnement en organes) pendant lequel les patients dans les groupes administration orale vs. administration intraveineuse nécessitaient un traitement inotrope. Les objectifs secondaires comprenaient les concentrations plasmiques de T3 et T4 et le nombre d’organes donnés après l’administration orale vs. intraveineuse de T4. Étude randomisée à double insu. Unité de soins intensifs médico-chirurgicale pour adultes. Trente-deux donneurs adultes d’organes solides. Les patients ont été randomisés à recevoir une dose orale ou intraveineuse de T4 (2 μg·kg−1). Tous les patients ont reçu une préparation orale et intraveineuse du médicament à l’étude, l’une étant un placebo. L’étude a été réalisée en double insu, et la randomisation s’est faite en blocs de quatre et de six. Le nombre et la durée des traitements inotropes / vasopresseurs et les taux sériques libres de T3 et T4 ont été déterminés une fois par heure jusqu’au don d’organe. Après l’administration de T4, tous les patients sont demeurés sous traitement inotrope / vasopresseur pour la même durée moyenne (ÉT) [93 (3) %] de la période de l’étude. Une réduction semblable et progressive a été observée dans le nombre et les dosages d’inotropes / vasopresseurs requis dans les deux groupes. Aucune différence dans les niveaux de T3 et T4 n’a été observée entre les groupes. La biodisponibilité orale de la T4 était de 93 % dans le groupe intraveineux à six heures et de 91 % globalement. À six heures, la surface sous la courbe moyenne pour la T4 était semblable dans le groupe intraveineux [92,2 (33); intervalle de confiance (IC) 95 % 76 à 108,4] et le groupe oral [86,1 (14); IC 95 % 79,4 à 92,8]. La T4 administrée par voie orale est bien absorbée et permet d’obtenir une biodisponibilité d’environ 91-93 % de la T4 intraveineuse chez les donneurs d’organes. Les besoins en agents inotropes et vasopresseurs et les réponses hémodynamiques suivant l’administration orale ou intraveineuse de thyroxine étaient comparables. La T4 orale est convenable pour le traitement hormonal chez les donneurs d’organes. Cette étude a été enregistrée au www.clinicaltrials.gov: NCT00238030.


  • Open Access

    Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study

    by Constantine J Karvellas, Thomas Lescot, Peter Goldberg, Michael D Sharpe, Juan J Ronco, Eberhard L Renner, Hina Vahidy, Zafrina Poonja, Prosanto Chaudhury, Norman M Kneteman, et al.

    Introduction: Critically ill cirrhosis patients awaiting liver transplantation (LT) often receive prioritization for organ allocation. Identification of patients most likely to benefit is essential. The purpose of this study was to examine whether the Sequential Organ Failure Assessment (SOFA) score can predict 90-day mortality in critically ill recipients of LT and whether it can predict receipt of LT among critically ill cirrhosis listed awaiting LT. Methods: We performed a multicenter retrospective cohort study consisting of two datasets: (a) all critically-ill cirrhosis patients requiring intensive care unit (ICU) admission before LT at five transplant centers in Canada from 2000 through 2009 (one site, 1990 through 2009), and (b) critically ill cirrhosis patients receiving LT from ICU (n = 115) and those listed but not receiving LT before death (n = 106) from two centers where complete data were available. Results: In the first dataset, 198 critically ill cirrhosis patients receiving LT (mean (SD) age 53 (10) years, 66% male, median (IQR) model for end-stage liver disease (MELD) 34 (26-39)) were included. Mean (SD) SOFA scores at ICU admission, at 48 hours, and at LT were 12.5 (4), 13.0 (5), and 14.0 (4). Survival at 90 days was 84% (n = 166). In multivariable analysis, only older age was independently associated with reduced 90-day survival (odds ratio (OR), 1.07; 95% CI, 1.01 to 1.14; P = 0.013). SOFA score did not predict 90-day mortality at any time. In the second dataset, 47.9% (n = 106) of cirrhosis patients listed for LT died in the ICU waiting for LT. In multivariable analysis, higher SOFA at 48 hours after admission was independently associated with lower probability of receiving LT (OR, 0.89; 95% CI, 0.82 to 0.97; P = 0.006). When including serum lactate and SOFA at 48 hours in the final model, elevated lactate (at 48 hours) was also significantly associated with lower likelihood of receiving LT (0.32; 0.17 to 0.61; P = 0.001). Conclusions: SOFA appears poor at predicting 90-day survival in critically ill cirrhosis patients after LT, but higher SOFA score and elevated lactate 48 hours after ICU admission are associated with a lower probability receiving LT. Older critically ill cirrhosis patients (older than 60) receiving LT have worse 90-day survival and should be considered for LT with caution.


  • Acute paralysis following “a bad potato”: A case of botulism

    by Mohit Bhutani, Edward Ralph, Michael D. Sharpe

    Intensivists often encounter patients with respiratory failure as a result of neuromuscular disease, however, acute neuromuscular syndromes are less common. We present a case of food borne Clostridium botulism and discuss the diagnostic and therapeutic considerations. A 35-yr-old healthy male presented with abdominal pain and blurred vision 12 hr after ingesting a “bad“ potato. During the next 17 hr, the patient demonstrated a gradual descending paralysis which ultimately resulted in no cranial nerve function and 0/5 strength in all extremities. Sensation was intact. The patient required intubation and mechanical ventilation. His blood count, biochemical profile, computerized tomography and magnetic resonance imaging of the head were normal. A lumbar puncture revealed no abnormalities. Due to the rapid deterioration and presentation of ’descending’ paralysis, botulism was suspected. The patient was treated empirically with botulinum anti-toxin. Samples of blood, stool and gastric contents were cultured for the presence of Clostridium botulinum and its toxin and these tests were positive for botulinum toxin A 12 days later. The patient’s neuromuscular function gradually improved over a prolonged period of time. Six and one-half months after his initial presentation, the patient was discharged home after completing an aggressive rehabilitation program. Botulism is a rare syndrome and presents as an acute, afebrile, descending paralysis beginning with the cranial nerves. If suspected, botulinum anti-toxin should be considered, particularly within the first 24 hr of onset of symptoms. Confirmation of the presence of botulinum requires days therefore the diagnosis and management rely on history and physical examination. Beaucoup de patients présentent une insuffisance respiratoire causée par une affection neuromusculaire, les syndromes neuromusculaires aigus étant plus rares. Nous présentons un cas d’intoxication alimentaire à Clostridium botulinum et discutons du diagnostic et du traitement. Un homme sain de 35 ans a consulté pour des douleurs abdominales et une vision floue 12 h après avoir mangé une «mauvaise patate». Pendant les 17 h suivantes, une paralysie descendante graduelle s’est installée et a finalement provoqué la perte de fonction des nerfs crâniens et réduit à 0/5 la force des extrémités. La sensation était intacte. Il a fallu intuber et ventiler le patient. La numération plaquettaire, le profil biochimique, la tomographie par ordinateur et l’imagerie par résonance magnétique de la tête étaient normaux. Une ponction lombaire n’a révélé aucune anomalie. Devant la détérioration rapide et la paralysie «descendante», nous avons pensé au botulisme. Un traitement empirique avec une antitoxine botulinique a été administré. Les échantillons de sang, de selles et du contenu gastrique ont été mis en culture pour vérifier la présence du Clostridium botulinum. La présence de la toxine botulinique type A a été révélée 12 jours plus tard. La fonction neuromusculaire s’est graduellement améliorée sur une longue période. Six mois et demi après sa première visite, le patient a pu partir après un programme de réadaptation complet et énergique. Syndrome rare, le botulisme se présente comme une paralysie aiguë, afébrile et descendante affectant d’abord les nerfs crâniens. S’il est soupçonné, il faut penser à l’antitoxine botulinique, surtout au cours des 24 premières heures de l’apparition des symptômes. La confirmation de la présence de Clostridium botulinum demandant des jours, le diagnostic et le traitement reposent sur l’histoire et l’examen physique.


  • Open Access

    The apnea test for brain death determination

    by Michael D. Sharpe, G. Bryan Young, Chris Harris

    Introduction: Problems associated with the standard apnea test relate to overshooting or undershooting the target PaCO2, potentially compromising the viability of organs for transplantation or...


  • Open Access

    Cardiac Drug Therapy, 6th Edition

    by Michael D. Sharpe, David O. Warner

  • Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study

    by Michael D. Sharpe, Cameron Ghent, David Grant, Gwendolyn L. A. Horbay, Janet McDougal, W. David Colby

    There is significant morbidity and mortality related to fungal infections in the solid-organ transplant population. A prospective, randomized, double-blind, placebo-controlled, restricted sequential design trial was performed in 71 adults undergoing orthotopic liver transplantation. Patients were randomly assigned to receive either itraconazole (5.0 mg/kg orally, preoperatively, 2.5 mg/kg orally, two times a day, postoperatively) or placebo. Therapy continued for a maximum of 56 days or until patient was discharged from hospital or met a predefined endpoint. Measurements included incidence of fungal colonization, superficial or systemic fungal infections requiring systemic therapy, adverse events, and mortality rate. This trial design supported the superiority of itraconazole in preventing fungal infections; nine patients in the placebo group (24%; 95% confidence interval, 0.118–0.412) and one patient in the itraconazole group (4%; 95% confidence interval, 0.001–0.204) developed fungal endpoints requiring therapy with amphotericin B (P =0.04, Fisher’s exact test). At the time of enrolment, fungal colonization occurred in 40% and 37% of itraconazole and placebo patients (P =0.43), respectively. Adverse events were reported by 97% and 100% of the intraconazole and placebo groups, respectively, and one itraconazole and six placebo-group patients died within the study period. There was no relation to trial medication for serious adverse events. Prophylaxis with itraconazole reduces fungal infections in patients undergoing orthotopic liver transplantation and is well tolerated.


  • Translaryngeal Tracheostomy: Experience of 340 Cases

    by Michael D. Sharpe, Lorne S. Parnes, John W. Drover, Chris Harris


  • Prolonged Desflurane Administration for Refractory Status Epilepticus

    by Michael D. Sharpe, G. Bryan Young, Seyed Mirsattari, Chris Harris